Contact
searchSearch
HMP Global
Login

Oncology

Featured

Efrat Dotan, MD; Mary Larse, MSN, RN, OCN; Meredith Pelster, MD, MSCI
Videos
Clinical Perspectives: A Case-Based Discussion of Targeted Therapy in Metastatic Pancreatic Cancer
11/02/2026
Efrat Dotan, MD; Mary Larsen, MSN, RN, OCN; Meredith Pelster, MD
In this case-based discussion, experts examine the phase 3 RASolute 302 efficacy and safety data for daraxonrasib, an FDA-approved RAS inhibitor for metastatic pancreatic adenocarcinoma (mPDAC). The panelists discuss how to interpret the...
In this case-based discussion, experts examine the phase 3 RASolute 302 efficacy and safety data for daraxonrasib, an FDA-approved RAS inhibitor for metastatic pancreatic adenocarcinoma (mPDAC). The panelists discuss how to interpret the...
In this case-based discussion,...
11/02/2026
Oncology
Filippo Pietrantonio, MD
Videos
Guiding Treatment Selection Through Molecular Testing in Metastatic Pancreatic Cancer
11/02/2026
Filippo Pietrantonio
Filippo Pietrantonio, MD, reviews the clinical decision-making behind the management of a patient with Lynch syndrome and MSI-H metastatic pancreatic cancer, highlighting the role of molecular testing and the selection of pembrolizumab...
Filippo Pietrantonio, MD, reviews the clinical decision-making behind the management of a patient with Lynch syndrome and MSI-H metastatic pancreatic cancer, highlighting the role of molecular testing and the selection of pembrolizumab...
Filippo Pietrantonio, MD,...
11/02/2026
Oncology
Joshua Sabari, MD; Julia Rotow, MD; Estelamari Rodriguez, MD, MPH
Videos
Round 3: Establishing the Frontline Standard
11/02/2026
Estelamari Rodriguez, MD, MPH; Joshua Sabari, MD; Julia Rotow, MD
In the final round, faculty consider a fit patient with relatively limited metastatic disease, exploring where osimertinib monotherapy may remain appropriate and how efficacy, tolerability, patient preferences, and treatment burden inform the...
In the final round, faculty consider a fit patient with relatively limited metastatic disease, exploring where osimertinib monotherapy may remain appropriate and how efficacy, tolerability, patient preferences, and treatment burden inform the...
In the final round, faculty...
11/02/2026
Oncology
Joshua Sabari, MD; Julia Rotow, MD; Estelamari Rodriguez, MD, MPH
Videos
Round 2: Managing Frontline Brain Metastases
11/02/2026
Estelamari Rodriguez, MD, MPH; Joshua Sabari, MD; Julia Rotow, MD
The discussion turns to a patient with small, asymptomatic brain metastases and additional high-risk features. Faculty examine how CNS efficacy data, molecular characteristics, and the potential role of CNS-directed therapy influence...
The discussion turns to a patient with small, asymptomatic brain metastases and additional high-risk features. Faculty examine how CNS efficacy data, molecular characteristics, and the potential role of CNS-directed therapy influence...
The discussion turns to a...
11/02/2026
Oncology
Joshua Sabari, MD; Julia Rotow, MD; Estelamari Rodriguez, MD, MPH
Videos
Round 1: Managing Patients With High Disease Burden
11/02/2026
Estelamari Rodriguez, MD, MPH; Joshua Sabari, MD; Julia Rotow, MD
The debate begins with a patient with extensive, symptomatic metastatic disease. Faculty explore how tumor burden, the need for durable disease control, and treatment tolerability influence the decision to intensify therapy upfront.
The debate begins with a patient with extensive, symptomatic metastatic disease. Faculty explore how tumor burden, the need for durable disease control, and treatment tolerability influence the decision to intensify therapy upfront.
The debate begins with a patient...
11/02/2026
Oncology
Efrat Dotan, MD; Mary Larse, MSN, RN, OCN; Meredith Pelster, MD, MSCI
Videos
Round 2: The Role of Targeted Therapy in mPDAC and Tolerability Considerations
11/02/2026
Efrat Dotan, MD; Mary Larsen, MSN, RN, OCN; Meredith Pelster, MD
The panel examines RASolute 302 efficacy findings in the overall study population, then takes a closer look at the safety data, discussing treatment-related adverse events and practical approaches to their recognition and management.
The panel examines RASolute 302 efficacy findings in the overall study population, then takes a closer look at the safety data, discussing treatment-related adverse events and practical approaches to their recognition and management.
The panel examines RASolute 302...
11/02/2026
Oncology
Efrat Dotan, MD; Mary Larse, MSN, RN, OCN; Meredith Pelster, MD, MSCI
Videos
Round 1: Interpreting Clinical Data for Targeted Therapy in mPDAC
11/02/2026
Efrat Dotan, MD; Mary Larsen, MSN, RN, OCN; Meredith Pelster, MD
A case involving a patient with a KRAS G12D mutation who progresses after first-line therapy prompts discussion of second-line treatment selection. The panel examines RASolute 302 efficacy findings in the RAS G12 population and provides an...
A case involving a patient with a KRAS G12D mutation who progresses after first-line therapy prompts discussion of second-line treatment selection. The panel examines RASolute 302 efficacy findings in the RAS G12 population and provides an...
A case involving a patient with...
11/02/2026
Oncology
Joshua Sabari, MD; Julia Rotow, MD; Estelamari Rodriguez, MD, MPH
Videos
Frontline Treatment Selection in EGFR-Mutated Metastatic NSCLC
11/02/2026
Estelamari Rodriguez, MD, MPH; Joshua Sabari, MD; Julia Rotow, MD
Thoracic oncology experts debate frontline treatment strategies for patients with EGFR-mutated metastatic non-small cell lung cancer (NSCLC). Through three patient cases, faculty explore when to intensify treatment upfront, where osimertinib...
Thoracic oncology experts debate frontline treatment strategies for patients with EGFR-mutated metastatic non-small cell lung cancer (NSCLC). Through three patient cases, faculty explore when to intensify treatment upfront, where osimertinib...
Thoracic oncology experts debate...
11/02/2026
Oncology
News
Phase 3 IMpactMF Trial of Imetelstat Discontinued After Unfavorable Overall Survival Assessment
10/30/2026
Emily Estrada
The phase 3 IMpactMF trial of imetelstat in patients with JAK inhibitor-relapsed or refractory myelofibrosis has been discontinued after an independent Data Monitoring Committee determined that the study was unlikely to meet its primary...
The phase 3 IMpactMF trial of imetelstat in patients with JAK inhibitor-relapsed or refractory myelofibrosis has been discontinued after an independent Data Monitoring Committee determined that the study was unlikely to meet its primary...
The phase 3 IMpactMF trial of...
10/30/2026
Oncology
News
Cosibelimab Receives NCCN Category 2A Recommendation for Locally Advanced Cutaneous Squamous Cell Carcinoma
10/30/2026
Emily Estrada
Updated NCCN guidelines include cosibelimab as a Category 2A recommended treatment option for patients with locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation, supported by clinical...
Updated NCCN guidelines include cosibelimab as a Category 2A recommended treatment option for patients with locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation, supported by clinical...
Updated NCCN guidelines include...
10/30/2026
Oncology
Tiffany Traina, MD
Videos
Optimizing Checkpoint Inhibitor Use Across Early-Stage and Metastatic Triple-Negative Breast Cancer
10/30/2026
Tiffany A. Traina, MD
Tiffany Traina, MD, discusses the role of immune checkpoint inhibitors in patients with early-stage and metastatic triple-negative breast cancer, highlighting KEYNOTE-522 findings, PD-L1-guided patient selection, limitations of immunotherapy...
Tiffany Traina, MD, discusses the role of immune checkpoint inhibitors in patients with early-stage and metastatic triple-negative breast cancer, highlighting KEYNOTE-522 findings, PD-L1-guided patient selection, limitations of immunotherapy...
Tiffany Traina, MD, discusses...
10/30/2026
Oncology

Videos

Efrat Dotan, MD; Mary Larse, MSN, RN, OCN; Meredith Pelster, MD, MSCI
Videos
Clinical Perspectives: A Case-Based Discussion of Targeted Therapy in Metastatic Pancreatic Cancer
11/02/2026
Efrat Dotan, MD; Mary Larsen, MSN, RN, OCN; Meredith Pelster, MD
In this case-based discussion, experts examine the phase 3 RASolute 302 efficacy and safety data for daraxonrasib, an FDA-approved RAS inhibitor for metastatic pancreatic adenocarcinoma (mPDAC). The panelists discuss how to interpret the...
In this case-based discussion, experts examine the phase 3 RASolute 302 efficacy and safety data for daraxonrasib, an FDA-approved RAS inhibitor for metastatic pancreatic adenocarcinoma (mPDAC). The panelists discuss how to interpret the...
In this case-based discussion,...
11/02/2026
Oncology
Filippo Pietrantonio, MD
Videos
Guiding Treatment Selection Through Molecular Testing in Metastatic Pancreatic Cancer
11/02/2026
Filippo Pietrantonio
Filippo Pietrantonio, MD, reviews the clinical decision-making behind the management of a patient with Lynch syndrome and MSI-H metastatic pancreatic cancer, highlighting the role of molecular testing and the selection of pembrolizumab...
Filippo Pietrantonio, MD, reviews the clinical decision-making behind the management of a patient with Lynch syndrome and MSI-H metastatic pancreatic cancer, highlighting the role of molecular testing and the selection of pembrolizumab...
Filippo Pietrantonio, MD,...
11/02/2026
Oncology
Joshua Sabari, MD; Julia Rotow, MD; Estelamari Rodriguez, MD, MPH
Videos
Round 3: Establishing the Frontline Standard
11/02/2026
Estelamari Rodriguez, MD, MPH; Joshua Sabari, MD; Julia Rotow, MD
In the final round, faculty consider a fit patient with relatively limited metastatic disease, exploring where osimertinib monotherapy may remain appropriate and how efficacy, tolerability, patient preferences, and treatment burden inform the...
In the final round, faculty consider a fit patient with relatively limited metastatic disease, exploring where osimertinib monotherapy may remain appropriate and how efficacy, tolerability, patient preferences, and treatment burden inform the...
In the final round, faculty...
11/02/2026
Oncology
Joshua Sabari, MD; Julia Rotow, MD; Estelamari Rodriguez, MD, MPH
Videos
Round 2: Managing Frontline Brain Metastases
11/02/2026
Estelamari Rodriguez, MD, MPH; Joshua Sabari, MD; Julia Rotow, MD
The discussion turns to a patient with small, asymptomatic brain metastases and additional high-risk features. Faculty examine how CNS efficacy data, molecular characteristics, and the potential role of CNS-directed therapy influence...
The discussion turns to a patient with small, asymptomatic brain metastases and additional high-risk features. Faculty examine how CNS efficacy data, molecular characteristics, and the potential role of CNS-directed therapy influence...
The discussion turns to a...
11/02/2026
Oncology
Joshua Sabari, MD; Julia Rotow, MD; Estelamari Rodriguez, MD, MPH
Videos
Round 1: Managing Patients With High Disease Burden
11/02/2026
Estelamari Rodriguez, MD, MPH; Joshua Sabari, MD; Julia Rotow, MD
The debate begins with a patient with extensive, symptomatic metastatic disease. Faculty explore how tumor burden, the need for durable disease control, and treatment tolerability influence the decision to intensify therapy upfront.
The debate begins with a patient with extensive, symptomatic metastatic disease. Faculty explore how tumor burden, the need for durable disease control, and treatment tolerability influence the decision to intensify therapy upfront.
The debate begins with a patient...
11/02/2026
Oncology
Efrat Dotan, MD; Mary Larse, MSN, RN, OCN; Meredith Pelster, MD, MSCI
Videos
Round 2: The Role of Targeted Therapy in mPDAC and Tolerability Considerations
11/02/2026
Efrat Dotan, MD; Mary Larsen, MSN, RN, OCN; Meredith Pelster, MD
The panel examines RASolute 302 efficacy findings in the overall study population, then takes a closer look at the safety data, discussing treatment-related adverse events and practical approaches to their recognition and management.
The panel examines RASolute 302 efficacy findings in the overall study population, then takes a closer look at the safety data, discussing treatment-related adverse events and practical approaches to their recognition and management.
The panel examines RASolute 302...
11/02/2026
Oncology
Efrat Dotan, MD; Mary Larse, MSN, RN, OCN; Meredith Pelster, MD, MSCI
Videos
Round 1: Interpreting Clinical Data for Targeted Therapy in mPDAC
11/02/2026
Efrat Dotan, MD; Mary Larsen, MSN, RN, OCN; Meredith Pelster, MD
A case involving a patient with a KRAS G12D mutation who progresses after first-line therapy prompts discussion of second-line treatment selection. The panel examines RASolute 302 efficacy findings in the RAS G12 population and provides an...
A case involving a patient with a KRAS G12D mutation who progresses after first-line therapy prompts discussion of second-line treatment selection. The panel examines RASolute 302 efficacy findings in the RAS G12 population and provides an...
A case involving a patient with...
11/02/2026
Oncology
Joshua Sabari, MD; Julia Rotow, MD; Estelamari Rodriguez, MD, MPH
Videos
Frontline Treatment Selection in EGFR-Mutated Metastatic NSCLC
11/02/2026
Estelamari Rodriguez, MD, MPH; Joshua Sabari, MD; Julia Rotow, MD
Thoracic oncology experts debate frontline treatment strategies for patients with EGFR-mutated metastatic non-small cell lung cancer (NSCLC). Through three patient cases, faculty explore when to intensify treatment upfront, where osimertinib...
Thoracic oncology experts debate frontline treatment strategies for patients with EGFR-mutated metastatic non-small cell lung cancer (NSCLC). Through three patient cases, faculty explore when to intensify treatment upfront, where osimertinib...
Thoracic oncology experts debate...
11/02/2026
Oncology
Tiffany Traina, MD
Videos
Optimizing Checkpoint Inhibitor Use Across Early-Stage and Metastatic Triple-Negative Breast Cancer
10/30/2026
Tiffany A. Traina, MD
Tiffany Traina, MD, discusses the role of immune checkpoint inhibitors in patients with early-stage and metastatic triple-negative breast cancer, highlighting KEYNOTE-522 findings, PD-L1-guided patient selection, limitations of immunotherapy...
Tiffany Traina, MD, discusses the role of immune checkpoint inhibitors in patients with early-stage and metastatic triple-negative breast cancer, highlighting KEYNOTE-522 findings, PD-L1-guided patient selection, limitations of immunotherapy...
Tiffany Traina, MD, discusses...
10/30/2026
Oncology
Sara Nunnery, MD
Videos
Oral SERDs and ESR1 Mutation Monitoring Reshape Treatment of HR-Positive Metastatic Breast Cancer
10/30/2026
Sara Nunnery, MD, MS
Sara Nunnery, MD, discusses advances in oral SERD therapy for HR-positive, HER2-negative metastatic breast cancer, highlighting ESR1 mutation testing, ctDNA guided treatment switching from SERENA-6, emerging endocrine therapy combinations,...
Sara Nunnery, MD, discusses advances in oral SERD therapy for HR-positive, HER2-negative metastatic breast cancer, highlighting ESR1 mutation testing, ctDNA guided treatment switching from SERENA-6, emerging endocrine therapy combinations,...
Sara Nunnery, MD, discusses...
10/30/2026
Oncology

Insights From the ASCO Annual Meeting

News
First-in-Class Hepcidin Inhibitor DISC-0974 Demonstrates Activity in Myelofibrosis-Associated Anemia
07/09/2026
Stephanie Holland
Results from the ongoing, phase 2 RALLY-MF trial demonstrated that DISC-0974 produced meaningful hematologic responses and improved fatigue in patients with myelofibrosis-associated anemia, supporting hepcidin inhibition as a potential...
Results from the ongoing, phase 2 RALLY-MF trial demonstrated that DISC-0974 produced meaningful hematologic responses and improved fatigue in patients with myelofibrosis-associated anemia, supporting hepcidin inhibition as a potential...
Results from the ongoing, phase...
07/09/2026
Oncology
News
Imetelstat Maintains Overall Survival Advantage Over Best Available Therapy in JAK Inhibitor–Relapsed or Refractory Myelofibrosis
07/09/2026
Stephanie Holland
Updated results from a post hoc analysis demonstrated that imetelstat continued to improve overall survival compared with best available therapy in patients with JAK inhibitor relapsed or refractory myelofibrosis, despite substantial changes...
Updated results from a post hoc analysis demonstrated that imetelstat continued to improve overall survival compared with best available therapy in patients with JAK inhibitor relapsed or refractory myelofibrosis, despite substantial changes...
Updated results from a post hoc...
07/09/2026
Oncology
Ramaswamy Govindan, MD
Videos
Adjuvant Erlotinib Following Complete Resection of EGFR-Mutant Non-Small Cell Lung Cancer Improves Disease Free Survival But Not Overall Survival
06/29/2026
Ramaswamy Govindan, MD
Ramaswamy Govindan, MD, discusses results from the ALCHEMIST trial evaluating adjuvant erlotinib in resected EGFR-mutant non–small cell lung cancer and the potential for ongoing biomarker studies to identify patients most likely to benefit...
Ramaswamy Govindan, MD, discusses results from the ALCHEMIST trial evaluating adjuvant erlotinib in resected EGFR-mutant non–small cell lung cancer and the potential for ongoing biomarker studies to identify patients most likely to benefit...
Ramaswamy Govindan, MD,...
06/29/2026
Oncology
Erika Hamilton, MD
Videos
Tucatinib Demonstrates Consistent Benefit Across First-Line HER2-Positive Metastatic Breast Cancer Populations
06/26/2026
Erika Hamilton, MD
Erika Hamilton, MD, discusses updated results from the HER2CLIMB-05 trial showing that tucatinib added to trastuzumab and pertuzumab maintenance therapy improved outcomes across multiple clinically relevant subgroups of patients with...
Erika Hamilton, MD, discusses updated results from the HER2CLIMB-05 trial showing that tucatinib added to trastuzumab and pertuzumab maintenance therapy improved outcomes across multiple clinically relevant subgroups of patients with...
Erika Hamilton, MD, discusses...
06/26/2026
Oncology
Bjørn Henning Grønberg, MD, PhD
Videos
Concurrent Radiotherapy, Chemotherapy, and Durvalumab Does Not Improve Outcomes in Extensive-Stage Small Cell Lung Cancer
06/26/2026
Bjørn Henning Grønberg, MD, PhD
Bjørn Henning Grønberg, MD, PhD, discusses results from a phase 3 randomized trial evaluating the addition of concurrent thoracic radiotherapy to platinum/etoposide chemotherapy plus durvalumab in patients with extensive-stage small cell lung...
Bjørn Henning Grønberg, MD, PhD, discusses results from a phase 3 randomized trial evaluating the addition of concurrent thoracic radiotherapy to platinum/etoposide chemotherapy plus durvalumab in patients with extensive-stage small cell lung...
Bjørn Henning Grønberg, MD, PhD,...
06/26/2026
Oncology
Peter O’Donnell, MD
Videos
Health-Related Quality of Life Preserved with Neoadjuvant and Adjuvant Enfortumab Vedotin plus Pembrolizumab in Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer
06/26/2026
Peter O'Donnell, MD
Peter O’Donnell, MD, of the University of Chicago, discusses health-related quality-of-life (HRQoL) findings from the phase 3 KEYNOTE-905 study evaluating perioperative enfortumab vedotin plus pembrolizumab in patients with muscle-invasive...
Peter O’Donnell, MD, of the University of Chicago, discusses health-related quality-of-life (HRQoL) findings from the phase 3 KEYNOTE-905 study evaluating perioperative enfortumab vedotin plus pembrolizumab in patients with muscle-invasive...
Peter O’Donnell, MD, of the...
06/26/2026
Oncology
Sanjay Popat, PhD, FRCP
Videos
Pralsetinib Shows Improved Response in RET Fusion–Positive Advanced or Metastatic Non–Small Cell Lung Cancer
06/25/2026
Sanjay Popat, PhD, FRCP
Sanjay Popat, PhD, FRCP, medical oncologist at The Royal Marsden Hospital in London, England, discusses results from the phase 3 AcceleRET-Lung trial evaluating first-line pralsetinib versus standard-of-care histology-specific chemotherapy...
Sanjay Popat, PhD, FRCP, medical oncologist at The Royal Marsden Hospital in London, England, discusses results from the phase 3 AcceleRET-Lung trial evaluating first-line pralsetinib versus standard-of-care histology-specific chemotherapy...
Sanjay Popat, PhD, FRCP, medical...
06/25/2026
Oncology
Walter Weber, MD
Videos
Prepectoral Implant Placement Improves Long-Term Quality of Life After Breast Reconstruction
06/24/2026
Walter Weber, MD
Walter Weber, MD, discusses results from the phase 3 PREPEC trial showing that prepectoral implant-based breast reconstruction significantly improved long-term quality of life and physical well-being compared with subpectoral reconstruction...
Walter Weber, MD, discusses results from the phase 3 PREPEC trial showing that prepectoral implant-based breast reconstruction significantly improved long-term quality of life and physical well-being compared with subpectoral reconstruction...
Walter Weber, MD, discusses...
06/24/2026
Oncology
Timothy Cloughesy, MD
Videos
Vorasidenib Maintains Durable Clinical Benefit With Consistent Safety in IDH-Mutated Glioma
06/24/2026
Timothy Cloughesy, MD
Timothy Cloughesy, MD, discusses updated results from the INDIGO trial showing durable disease control, prolonged progression-free survival, and sustained safety with vorasidenib in patients with IDH-mutant grade 2 gliomas.
Timothy Cloughesy, MD, discusses updated results from the INDIGO trial showing durable disease control, prolonged progression-free survival, and sustained safety with vorasidenib in patients with IDH-mutant grade 2 gliomas.
Timothy Cloughesy, MD, discusses...
06/24/2026
Oncology
Peter Schmid, MD, PhD
Videos
Giredestrant Improves Outcomes Regardless of Menopausal Status in Early Breast Cancer
06/24/2026
Peter Schmid, MD, PhD
Peter Schmid, MD, PhD, discusses subgroup analysis results from the lidERA trial showing that giredestrant improved invasive disease-free and distant recurrence-free survival across premenopausal and postmenopausal patients with ER-positive,...
Peter Schmid, MD, PhD, discusses subgroup analysis results from the lidERA trial showing that giredestrant improved invasive disease-free and distant recurrence-free survival across premenopausal and postmenopausal patients with ER-positive,...
Peter Schmid, MD, PhD, discusses...
06/24/2026
Oncology

Insights From the ESMO Congress

Vanda Salutari, MD, Policlinico Gemelli
Videos
BEHOLD-1: Updated Results With Mocertatug Rezetecan in Platinum-Resistant Ovarian Cancer
10/29/2026
Vanda Salutari, MD, discusses updated results from the phase 1 BEHOLD-1 trial evaluating the B7-H4-directed antibody-drug conjugate Mo-Rez in platinum-resistant ovarian cancer, highlighting durable antitumor activity, promising...
Vanda Salutari, MD, discusses updated results from the phase 1 BEHOLD-1 trial evaluating the B7-H4-directed antibody-drug conjugate Mo-Rez in platinum-resistant ovarian cancer, highlighting durable antitumor activity, promising...
Vanda Salutari, MD, discusses...
10/29/2026
Oncology
News
NETSARC+ Study Identifies Tumor Location and Size as Prognostic Factors in Patients With Desmoid Tumors
10/28/2026
Emily Estrada
Results from a large NETSARC+ registry analysis demonstrated a substantial decline in surgical management of desmoid tumors over time and identified tumor size and anatomical location as prognostic factors for progression-free survival,...
Results from a large NETSARC+ registry analysis demonstrated a substantial decline in surgical management of desmoid tumors over time and identified tumor size and anatomical location as prognostic factors for progression-free survival,...
Results from a large NETSARC+...
10/28/2026
Oncology
News
Reduced-Frequency Immunotherapy Fails to Demonstrate Noninferiority in Advanced Cancer in Phase 3 MOIO Trial
10/26/2026
Emily Estrada
Results from the phase 3 MOIO trial demonstrated that reduced-frequency immune checkpoint inhibitor treatment failed to establish progression-free survival noninferiority compared with standard dosing in patients with responding advanced or...
Results from the phase 3 MOIO trial demonstrated that reduced-frequency immune checkpoint inhibitor treatment failed to establish progression-free survival noninferiority compared with standard dosing in patients with responding advanced or...
Results from the phase 3 MOIO...
10/26/2026
Oncology
News
Risvutatug Rezetecan Reduces Progression Risk by 67% in Previously Treated Relapsed or Refractory Osteosarcoma
10/26/2026
Emily Estrada
Results from the phase 3 ARTEMIS-011 trial showed that risvutatug rezetecan significantly prolonged progression-free survival compared with gemcitabine plus docetaxel in heavily pretreated patients with relapsed or refractory osteosarcoma,...
Results from the phase 3 ARTEMIS-011 trial showed that risvutatug rezetecan significantly prolonged progression-free survival compared with gemcitabine plus docetaxel in heavily pretreated patients with relapsed or refractory osteosarcoma,...
Results from the phase 3...
10/26/2026
Oncology
News
Sacituzumab Tirumotecan Outperforms Chemotherapy in Advanced or Recurrent Endometrial Cancer
10/26/2026
Stephanie Holland
Results from the phase 3 TroFuse-005 trial demonstrated significant improvements in survival and response with sacituzumab tirumotecan compared with physician's choice chemotherapy in previously treated advanced or recurrent endometrial...
Results from the phase 3 TroFuse-005 trial demonstrated significant improvements in survival and response with sacituzumab tirumotecan compared with physician's choice chemotherapy in previously treated advanced or recurrent endometrial...
Results from the phase 3...
10/26/2026
Oncology
Brian Slomovitz, MD
Videos
KEYNOTE-C93 Demonstrates Superior PFS With Pembrolizumab Monotherapy in dMMR Endometrial Cancer
10/26/2026
Brian M. Slomovitz, MD
Brian Slomovitz, MD, discusses results from the phase 3 KEYNOTE-C93 trial evaluating first-line pembrolizumab monotherapy versus carboplatin plus paclitaxel in advanced or recurrent mismatch repair–deficient endometrial cancer, highlighting...
Brian Slomovitz, MD, discusses results from the phase 3 KEYNOTE-C93 trial evaluating first-line pembrolizumab monotherapy versus carboplatin plus paclitaxel in advanced or recurrent mismatch repair–deficient endometrial cancer, highlighting...
Brian Slomovitz, MD, discusses...
10/26/2026
Oncology
News
Phase 3 Trial Demonstrates Survival Benefit With Ivonescimab Plus Chemotherapy in Advanced Biliary Tract Cancer
10/25/2026
Stephanie Holland
Results from a phase 3 trial demonstrated that ivonescimab plus gemcitabine and cisplatin significantly improved survival and response compared with durvalumab plus chemotherapy in advanced biliary tract cancer, supporting the PD-1/VEGF...
Results from a phase 3 trial demonstrated that ivonescimab plus gemcitabine and cisplatin significantly improved survival and response compared with durvalumab plus chemotherapy in advanced biliary tract cancer, supporting the PD-1/VEGF...
Results from a phase 3 trial...
10/25/2026
Oncology
News
Sonesitatug Vedotin Significantly Improves Overall Survival in CLDN18.2-Positive Advanced Gastroesophageal Cancer
10/25/2026
Stephanie Holland
Results from the phase 3 CLARITY-Gastric 01 trial demonstrated significant overall survival benefits with sonesitatug vedotin in previously treated CLDN18.2-positive advanced gastroesophageal cancer, supporting the antibody-drug conjugate as...
Results from the phase 3 CLARITY-Gastric 01 trial demonstrated significant overall survival benefits with sonesitatug vedotin in previously treated CLDN18.2-positive advanced gastroesophageal cancer, supporting the antibody-drug conjugate as...
Results from the phase 3...
10/25/2026
Oncology
News
Osimertinib Plus Savolitinib Outperforms Chemotherapy in EGFR-Mutated, MET-Altered Advanced NSCLC Following Osimertinib
10/25/2026
Stephanie Holland
Results from the phase 3 SAFFRON trial demonstrated that osimertinib plus savolitinib significantly improved survival compared with platinum-based chemotherapy in patients with EGFR-mutated, MET-altered advanced non-small cell lung cancer...
Results from the phase 3 SAFFRON trial demonstrated that osimertinib plus savolitinib significantly improved survival compared with platinum-based chemotherapy in patients with EGFR-mutated, MET-altered advanced non-small cell lung cancer...
Results from the phase 3 SAFFRON...
10/25/2026
Oncology
Ferdinandos Skoulidis, MD, PhD
Videos
KRAScendo-1: Divarasib Significantly Improves Survival Over Sotorasib or Adagrasib in KRAS G12C-Mutated Non-Small Cell Lung Cancer
10/25/2026
Ferdinandos Skoulidis, MD, PhD
Ferdinandos Skoulidis, MD, PhD, discusses results from the phase 3 KRAScendo-1 trial demonstrating that divarasib significantly improved survival and response compared with sotorasib or adagrasib in previously treated patients with locally...
Ferdinandos Skoulidis, MD, PhD, discusses results from the phase 3 KRAScendo-1 trial demonstrating that divarasib significantly improved survival and response compared with sotorasib or adagrasib in previously treated patients with locally...
Ferdinandos Skoulidis, MD, PhD,...
10/25/2026
Oncology

Live Meetings

Recent News

News
Phase 3 IMpactMF Trial of Imetelstat Discontinued After Unfavorable Overall Survival Assessment
10/30/2026
Emily Estrada
The phase 3 IMpactMF trial of imetelstat in patients with JAK inhibitor-relapsed or refractory myelofibrosis has been discontinued after an independent Data Monitoring Committee determined that the study was unlikely to meet its primary...
The phase 3 IMpactMF trial of imetelstat in patients with JAK inhibitor-relapsed or refractory myelofibrosis has been discontinued after an independent Data Monitoring Committee determined that the study was unlikely to meet its primary...
The phase 3 IMpactMF trial of...
10/30/2026
Oncology
News
Cosibelimab Receives NCCN Category 2A Recommendation for Locally Advanced Cutaneous Squamous Cell Carcinoma
10/30/2026
Emily Estrada
Updated NCCN guidelines include cosibelimab as a Category 2A recommended treatment option for patients with locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation, supported by clinical...
Updated NCCN guidelines include cosibelimab as a Category 2A recommended treatment option for patients with locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation, supported by clinical...
Updated NCCN guidelines include...
10/30/2026
Oncology
News
Petosemtamab Plus Pembrolizumab Significantly Improves Overall Survival in Patients With Head and Neck Squamous Cell Carcinoma
10/30/2026
Emily Estrada
Results from the phase 3 LiGeR-HN1 trial demonstrated that petosemtamab plus pembrolizumab significantly improved overall survival and objective response compared with pembrolizumab alone in patients with PD-L1-positive recurrent or...
Results from the phase 3 LiGeR-HN1 trial demonstrated that petosemtamab plus pembrolizumab significantly improved overall survival and objective response compared with pembrolizumab alone in patients with PD-L1-positive recurrent or...
Results from the phase 3...
10/30/2026
Oncology
News
Relacorilant Plus Nab-Paclitaxel and Bevacizumab Demonstrates 59% Response Rate in Platinum-Resistant Ovarian Cancer
10/30/2026
Stephanie Holland
Results from the phase 2 BELLA trial demonstrated encouraging progression-free survival and response with relacorilant plus nab-paclitaxel and bevacizumab in patients with platinum-resistant ovarian cancer, with more pronounced activity among...
Results from the phase 2 BELLA trial demonstrated encouraging progression-free survival and response with relacorilant plus nab-paclitaxel and bevacizumab in patients with platinum-resistant ovarian cancer, with more pronounced activity among...
Results from the phase 2 BELLA...
10/30/2026
Oncology
News
Updated ASTRO Guidelines Expand Role of Hypofractionated Radiotherapy in Localized Prostate Cancer
10/30/2026
Stephanie Holland
Updated ASTRO clinical practice guidelines recommend moderate hypofractionated radiotherapy over conventional fractionation across all localized prostate cancer risk groups and expand the role of ultrahypofractionation, including stereotactic...
Updated ASTRO clinical practice guidelines recommend moderate hypofractionated radiotherapy over conventional fractionation across all localized prostate cancer risk groups and expand the role of ultrahypofractionation, including stereotactic...
Updated ASTRO clinical practice...
10/30/2026
Oncology
News
Real-World Study Demonstrates Clinical Activity of Lurbinectedin in Previously Treated Small Cell Lung Cancer
10/28/2026
Emily Estrada
Results from the phase 4 Jazz EMERGE 402 study demonstrated clinically meaningful antitumor activity with lurbinectedin in previously treated small cell lung cancer, with lower response rates among patients with baseline central nervous...
Results from the phase 4 Jazz EMERGE 402 study demonstrated clinically meaningful antitumor activity with lurbinectedin in previously treated small cell lung cancer, with lower response rates among patients with baseline central nervous...
Results from the phase 4 Jazz...
10/28/2026
Oncology
News
NETSARC+ Study Identifies Tumor Location and Size as Prognostic Factors in Patients With Desmoid Tumors
10/28/2026
Emily Estrada
Results from a large NETSARC+ registry analysis demonstrated a substantial decline in surgical management of desmoid tumors over time and identified tumor size and anatomical location as prognostic factors for progression-free survival,...
Results from a large NETSARC+ registry analysis demonstrated a substantial decline in surgical management of desmoid tumors over time and identified tumor size and anatomical location as prognostic factors for progression-free survival,...
Results from a large NETSARC+...
10/28/2026
Oncology
News
G-CSF Prophylaxis Reduces Incidence of Febrile Neutropenia Without Compromising Chemoimmunotherapy Outcomes in Patients With Small Cell Lung Cancer
10/28/2026
Emily Estrada
Results from a multicenter, retrospective trial demonstrated that granulocyte colony-stimulating factor prophylaxis was associated with significantly reduced febrile neutropenia rates and fewer related acute-care visits in patients with small...
Results from a multicenter, retrospective trial demonstrated that granulocyte colony-stimulating factor prophylaxis was associated with significantly reduced febrile neutropenia rates and fewer related acute-care visits in patients with small...
Results from a multicenter,...
10/28/2026
Oncology
News
Tambotatug Pelitecan Significantly Improves Overall Survival in Patients With Relapsed Small Cell Lung Cancer
10/28/2026
Emily Estrada
Results from the phase 3 TAISHAN-302 trial demonstrated that tambotatug pelitecan significantly improved overall survival, progression-free survival, and objective response compared with topotecan in patients with relapsed small cell lung...
Results from the phase 3 TAISHAN-302 trial demonstrated that tambotatug pelitecan significantly improved overall survival, progression-free survival, and objective response compared with topotecan in patients with relapsed small cell lung...
Results from the phase 3...
10/28/2026
Oncology
News
Oral Hypomethylating Agents Show Comparable Hematologic Toxicity to Intravenous Therapy in Patients With Myelodysplastic Syndromes and Acute Myeloid Leukemia
10/28/2026
Emily Estrada
Results from a multicenter retrospective study found that no statistically significant differences in hematologic toxicity between oral and intravenous hypomethylating agents in patients with myelodysplastic syndromes or acute myeloid...
Results from a multicenter retrospective study found that no statistically significant differences in hematologic toxicity between oral and intravenous hypomethylating agents in patients with myelodysplastic syndromes or acute myeloid...
Results from a multicenter...
10/28/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use